ES2531396T3 - Proceso para preparar compuestos de piridinona - Google Patents

Proceso para preparar compuestos de piridinona Download PDF

Info

Publication number
ES2531396T3
ES2531396T3 ES09703743T ES09703743T ES2531396T3 ES 2531396 T3 ES2531396 T3 ES 2531396T3 ES 09703743 T ES09703743 T ES 09703743T ES 09703743 T ES09703743 T ES 09703743T ES 2531396 T3 ES2531396 T3 ES 2531396T3
Authority
ES
Spain
Prior art keywords
formula
compound
haloalkyl
halogen
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09703743T
Other languages
English (en)
Inventor
Robert C Livingston
William P Gallagher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2531396T3 publication Critical patent/ES2531396T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un proceso para preparar un compuesto de Fórmula (I):**Fórmula** que comprende las etapas de: (a) hacer reaccionar un compuesto de ácido carboxílico de Fórmula (III):**Fórmula** o un compuesto de ácido carboxílico activado del mismo, y un compuesto de anilina de Fórmula (II):**Fórmula** en la que PAm es un grupo amino protegido, seleccionado entre iminas, alquilaminas, arilaminas, carbamatos, amidas, imidas, bencilaminas, alilaminas, sililaminas, fosfonamidas, sulfonamidas y triazinanonas, para proporcionar un compuesto de Fórmula (IV):**Fórmula** y (b) convertir dicho grupo amino protegido unido a dicho compuesto de Fórmula (IV) en un grupo amino para proporcionar dicho compuesto de Fórmula (I);**Fórmula** en la que: Gis**Fórmula** cada R1 es independientemente alquilo, haloalquilo, halógeno o CN; cada R2 es independientemente alquilo, haloalquilo, halógeno o CN; R3 es fenilo sustituido con alquilo, haloalquilo, halógeno o CN; cada R4 es independientemente alquilo, haloalquilo, alcoxi, halógeno o CN; m es cero, 1, 2, 3 o 4; n es cero, 1, 2 o 3; p es cero, 1 o 2; y q es cero, 1, 2 o 3.
ES09703743T 2008-01-23 2009-01-22 Proceso para preparar compuestos de piridinona Active ES2531396T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2284808P 2008-01-23 2008-01-23
US12193108P 2008-12-12 2008-12-12
PCT/US2009/031665 WO2009094427A1 (en) 2008-01-23 2009-01-22 4-pyridinone compounds and their use for cancer

Publications (1)

Publication Number Publication Date
ES2531396T3 true ES2531396T3 (es) 2015-03-13

Family

ID=40668147

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09703743T Active ES2531396T3 (es) 2008-01-23 2009-01-22 Proceso para preparar compuestos de piridinona

Country Status (7)

Country Link
US (2) US8558000B2 (es)
EP (1) EP2235001B1 (es)
JP (1) JP5693239B2 (es)
KR (1) KR101608096B1 (es)
CN (1) CN101977905B (es)
ES (1) ES2531396T3 (es)
WO (1) WO2009094427A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094417A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
SG184891A1 (en) 2010-04-30 2012-11-29 Bristol Myers Squibb Co Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
HK1202450A1 (zh) 2011-11-22 2015-10-02 Deciphera Pharmaceuticals, Llc. 表現出抗癌和抗增殖活性的吡啶酮酰胺以及類似物
EP2810937B1 (en) 2012-01-31 2016-11-30 Daiichi Sankyo Company, Limited Pyridone derivative
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
MX2015001424A (es) 2012-07-28 2016-03-09 Calitor Sciences Llc Compuestos pirazolona sustituidos y metodos de uso.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
CN105153026B (zh) * 2015-08-21 2018-02-02 江西科技师范大学 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用
CN105924389A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 瑞戈非尼中间体的制备方法
WO2019186429A1 (en) * 2018-03-30 2019-10-03 Sun Pharmaceutical Industries Limited A process for the preparation of bosutinib
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646202A (en) 1967-11-22 1972-02-29 Merck & Co Inc Liver fluke compositions containing salicylic acid derivatives
US4547218A (en) 1982-10-18 1985-10-15 The Dow Chemical Company Certain 3-nitro-6-phenoxy-2-pyridyl-oxy-propionates having herbicidal activity
GB8925368D0 (en) * 1989-11-09 1989-12-28 Oppolzer Wolfgang Process for preparing enatiomerically pure alpha-amino acids
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
CA2314869A1 (en) 1997-12-22 1999-07-01 William Leonard Scott Catalyst and method for amide formation
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1344525A4 (en) 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
WO2003045921A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US6806221B2 (en) 2002-07-15 2004-10-19 Dow Global Technologies Inc. Method for preparing a spray-dried composition for use as a polymerization catalyst
EP1643991B1 (en) 2003-07-11 2014-03-12 Merck Patent GmbH Benzimidazole carboxamides as raf kinase inhibitors
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
DE10357510A1 (de) 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
WO2006071960A2 (en) 2004-12-28 2006-07-06 Kinex Pharmaceuticals, Llc Compositions and methods of treating cell proliferation disorders
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
AR057808A1 (es) 2005-09-13 2007-12-19 Bayer Cropscience Ag Derivados fungicidas de fenilamidina sustituida con piridiniloxi
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2378704T3 (es) 2006-01-27 2012-04-17 Array Biopharma, Inc. Activadores de la glucocinasa
EP1989211A2 (en) 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterobicyclic thiophene compounds for the treatment of cancer
CA2645137A1 (en) * 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
WO2008035209A2 (en) 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP2061761A1 (en) 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
CN101535264B (zh) * 2006-11-08 2012-11-28 百时美施贵宝公司 吡啶酮化合物

Also Published As

Publication number Publication date
WO2009094427A1 (en) 2009-07-30
US8754230B2 (en) 2014-06-17
EP2235001B1 (en) 2014-12-24
EP2235001A1 (en) 2010-10-06
US20110295015A1 (en) 2011-12-01
US8558000B2 (en) 2013-10-15
US20140012007A1 (en) 2014-01-09
CN101977905A (zh) 2011-02-16
JP2011510089A (ja) 2011-03-31
CN101977905B (zh) 2014-07-02
KR101608096B1 (ko) 2016-03-31
JP5693239B2 (ja) 2015-04-01
KR20100118581A (ko) 2010-11-05

Similar Documents

Publication Publication Date Title
ES2531396T3 (es) Proceso para preparar compuestos de piridinona
PE20141698A1 (es) Proceso para la preparacion de derivados de l-alanina protegidos
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
CR20190039A (es) ACETAMIDAS SUSTITUIDAS POR N-(HETERO)-ARILO Y 2-(HETERO)-ARILO (Divisional 2011-0520)
ATE469233T1 (de) Herstellungsverfahren für optisch aktive chirale amine
ES2531324T3 (es) Intermedio para producir un derivado de gamma-aminoácido bicíclico
DOP2011000061A (es) Compuestos de pirrol
MX394672B (es) Compuestos de n-(3-fluoropropil)-pirrolidina sustituidos novedosos, procesos para su preparacion y usos terapeuticos de los mismos.
RU2012103850A (ru) Би-арил-мета-пиримидиновые ингибиторы киназ
BR112012020986A2 (pt) composto de amina cíclica e acaricida
EA201170096A1 (ru) Замещенные производные пиримидона
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
CO6300859A2 (es) Metodos para inhibidir las respuestas del etileno en plantas usando compuestos de cilpropeno amina
BRPI0900983A2 (pt) compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos
MX2020011671A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
BRPI0713314A2 (pt) Processo para a preparação de 3-(2-hidróxi-5-fenil substituído)-n-alquil-3-fenilpropilaminas
EA201200282A1 (ru) Региоселективное получение производных 2-амино-5-трифторметилпиримидина
BR112012030534A2 (pt) moduladores de receptores 5-ht e métodos de uso dos mesmos
SE0403085D0 (sv) Novel componds
BRPI0812829A2 (pt) Processo para o acoplamento catalisado por paládio de alcinas terminais com tosilatos de arila
BRPI0907052B8 (pt) processo para a preparação de compostos
EA201200726A1 (ru) Способ синтеза, кристаллическая форма 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)ил]пропокси}бензамид гидрохлорида и фармацевтические композиции, которые ее содержат
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
EA200870038A1 (ru) Способ получения аминов